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Defining the functional attributes and the origin  



















manner. Historical  landmarks  (reviewed  in  refs.  9  and  21) 
include the identification of the sternzellen by von Kupffer in 
1876 and the first liver biopsy by Erlich and Lucatello in 1890. 














































Sinusoidal events in the development of liver fibrosis. Injury to hepatocytes results in the recruitment and stimulation of inflammatory cells, as 
well as the stimulation of resident inflammatory cells (including Kupffer cells). Factors released by these inflammatory cells lead to transformation 
of HSCs into a myofibroblast-like phenotype. HSC activation leads to accumulation of scar (fibrillar) ECM. The presence of a fibrillar ECM in the 
Disse space has consequences for hepatocyte function, leading to the loss of microvilli and endothelial fenestrae. Therefore, the loss of normal 
tissue architecture contributes to impairment of organ function. Figure modified with permission from Journal of Biological Chemistry (119).
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Representative examples of innate immune cell manipulation in animal models of liver fibrosis
Cell type Method of inducing fibrosis Method of cell manipulation Effect on fibrosis Refs.
Macrophages CCl4 intoxication Selective depletion of macrophages  Functionally distinct subpopulations  62 
   during liver injury and repair  of macrophages in the same tissue  
    have critical roles in both the  
    injury and recovery phases of  
    inflammatory scarring
Mast cells In rats: bile duct resection, CCl4  Mast cell–deficient mutant  No effect on development  66 
  intoxication, or porcine serum;   Ws/Ws rats and W/Wv mice  of liver fibrosis 
  in mice: bile duct resection or  
  CCl4 intoxication
Neutrophils BDL In rats: administration of neutrophil- No effect on hepatic fibrogenesis 68 
   specific antiserum; in mice: transgenic  
   expression of IL-8 causes an underlying  
   defect in neutrophil function
	 Administration of  Cxcr2–/– mice with resultant 50%  No effect on hepatic fibrosis 69 
  α-naphthylisothiocyanate  reduction in neutrophil recruitment
NK cells 3,5-diethoxycarbonyl-1,4- Activation and depletion of NK cells NK cells ameliorate liver fibrosis  63 
  dihydrocollidine diet or    by killing activated HSCs 
  CCl4 intoxication
Cxcr2–/–, CXC chemokine receptor 2–deficient.
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Representative examples of adaptive immune cell manipulation in animal models of liver fibrosis
Cell type Method of inducing fibrosis Cell type affected or manipulated Effect on fibrosis Refs.
T cells CCl4 intoxication or thioacetamide Transgenic mice with hepatocyte  Fibrosis promoted by CD8+ T cells in adoptive  74 
   expression of rat IL-10; adoptive   transfer experiment; CD8+ T cell–mediated  
   transfer of various lymphocyte   disease is attenuated by recombinant IL-10 
   subsets to SCID mice
 CCl4 intoxication Series of CCl4-induced liver injury  CD4+, CD8+, and γδ T cells do not  75 
   experiments with mice that lack   substantially affect hepatic fibrosis 
   CD4+ T cells, CD8+ T cells, γδ  
   T cells, or both B and T cells
 Infection with Schistosoma mansoni Treatment of S. mansoni–infected  Development of hepatic fibrosis blocked  76 
   mice with an inhibitor of IL-13  by IL-13 inhibitor during a Th2-dominated  
    inflammatory response
B cells CCl4 intoxication B cell–deficient mice Absence of B cells attenuates liver fibrosis in  77 
    an antibody- and T cell–independent manner
 Infection with S. mansoni B cell–deficient mice Increased hepatic fibrosis 120
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Repertoire of activities of the activated myofibroblast-like HSC. Activated HSCs, which are myofibroblast-like in phenotype, demonstrate a 
plastic and metabolically active phenotype that is proliferative, fibrogenic, and contractile. HSCs also release mediators that regulate ECM 
degradation (MMPs and TIMPs), chemotaxis, and leukocyte chemoattraction. The shedding of retinoids might be a critical, though as yet 
poorly defined, signal regulating fibrogenesis. During resolution of liver injury, activated HSCs and myofibroblasts have been demonstrated 
to undergo apoptosis. It is also possible that spontaneous reversion to a more quiescent phenotype might occur. Figure modified with per-
mission from Journal of Biological Chemistry (119).
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Diagramatic representation of the possible 
sources of liver myofibroblasts. There is con-
siderable evidence supporting the notion that 
HSCs are a major source of myofibroblasts in 
the injured liver. Additionally, contributions to 
the myofibroblast population might come from 
portal myofibroblasts. Most recently, BM stem 
cells have been demonstrated to contribute to 
the inflammatory cell population and the myo-
fibroblast population in the injured liver, which 
might occur directly or through an intermedi-
ary cell, such as a quiescent HSC or CD45+ 
fibrocyte. Research is currently underway to 
determine the role of EMT in the development 
of liver myofibroblasts.
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Liver cirrhosis is an example of dynamic wound healing. Damage to the normal liver (i) results in inflammation and activation of HSCs (ii; identi-
fied by immunohistochemistry, with staining for α-SMA [brown]) to secrete fibrillar collagens, culminating in the development of fibrosis (iii) and 
ultimately cirrhosis (iv). Withdrawal of the injurious agent can allow remodeling of the fibrillar matrix, leading to attenuated cirrhosis (v). Spontane-
ous resolution of fibrosis after removal of injury results in a return to near-normal architecture (vi). Whether complete resolution of cirrhosis can 
occur is currently unknown. Figure modified with permission from BMJ (3).
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